Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transfusion-dependent Iron Overload”

28 trials

Showing 20 of 28 results

Large-scale testing (Phase 3)Study completedNCT01825512
What this trial is testing

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Who this might be right for
Chronic Iron Overload
Consorzio per Valutazioni Biologiche e Farmacologiche 435
Not applicableStudy completedNCT01874405
What this trial is testing

Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy

Who this might be right for
Iron Overload
University of Campania Luigi Vanvitelli 80
Large-scale testing (Phase 3)Study completedNCT00171821
What this trial is testing

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Who this might be right for
Transfusion-dependent Iron Overload
Novartis Pharmaceuticals 1,784
Testing effectiveness (Phase 2)Study completedNCT02477631
What this trial is testing

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Who this might be right for
Myelodysplastic Syndrome With Low-grade LesionsIron Overload Due to Repeated Red Blood Cell Transfusions
Sheba Medical Center 19
Testing effectiveness (Phase 2)Ended earlyNCT01459718
What this trial is testing

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Who this might be right for
Transfusion-dependent β-thalassemia PatientsCardiac Iron Overload
Novartis Pharmaceuticals 32
Testing effectiveness (Phase 2)Study completedNCT05355766
What this trial is testing

Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients

Who this might be right for
ThalassemiaIron Overload
Hangzhou Zede Pharma-Tech Co., Ltd. 16
Testing effectiveness (Phase 2)Study completedNCT01709032
What this trial is testing

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Who this might be right for
Thalassemia Major With Severe Transfusional Iron Overload
Children's Hospital of Philadelphia 9
Large-scale testing (Phase 3)Study completedNCT00529152
What this trial is testing

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

Who this might be right for
Iron Overload
ApoPharma 100
Not applicableStudy completedNCT02090699
What this trial is testing

MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias

Who this might be right for
Thalassemia MajorChronic Blood Transfusion Related Iron Overload
University Health Network, Toronto 42
Testing effectiveness (Phase 2)Study completedNCT02435212
What this trial is testing

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Who this might be right for
Transfusion-dependent Anemia
Novartis Pharmaceuticals 224
Early research (Phase 1)Ended earlyNCT02274233
What this trial is testing

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Who this might be right for
Iron OverloadBeta-Thalassemia
Sideris Pharmaceuticals 24
Testing effectiveness (Phase 2)WithdrawnNCT03801889
What this trial is testing

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Who this might be right for
Iron OverloadBeta-Thalassemia
Abfero Pharmaceuticals, Inc
Testing effectiveness (Phase 2)Study completedNCT00873041
What this trial is testing

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

Who this might be right for
Non-transfusion Dependent Thalassemia
Novartis Pharmaceuticals 166
Post-approval studies (Phase 4)Study completedNCT00481143
What this trial is testing

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Who this might be right for
Myelodysplastic SyndromesTransfusion Dependent Iron Overload
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Ended earlyNCT02943668
What this trial is testing

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Who this might be right for
AnemiaMyelodysplastic Syndrome
Fred Hutchinson Cancer Center 2
Not applicableStudy completedNCT00466063
What this trial is testing

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Who this might be right for
Anemia
Novartis Pharmaceuticals 108
Post-approval studies (Phase 4)Ended earlyNCT01818726
What this trial is testing

Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients

Who this might be right for
Aplastic Anemia
Novartis Pharmaceuticals 15
Post-approval studies (Phase 4)Study completedNCT03591575
What this trial is testing

Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children

Who this might be right for
Beta Thalassemia Major AnemiaIron Overload
Chiesi Canada Corp 64
Testing effectiveness (Phase 2)Study completedNCT00349453
What this trial is testing

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

Who this might be right for
Hemochromatosis
Lipomed 24
Testing effectiveness (Phase 2)Ended earlyNCT03381833
What this trial is testing

A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia

Who this might be right for
Beta-Thalassemia
La Jolla Pharmaceutical Company 84
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation